<DOC>
	<DOC>NCT01512095</DOC>
	<brief_summary>This trial is conducted in Europe and United States of America (USA). The aim of this trial is to examine the bioequivalence (assessment of the expected biological equivalence of two pharmaceutical drug products with identical active ingredient) of Norditropin速 versus Nutropin AQ速 in healthy adult volunteers.</brief_summary>
	<brief_title>Bioequivalence of Two Products (Norditropin速 Versus Nutropin AQ速) in Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>No previous exposure to recombinant human GH (growth hormone)or IGFI (insulinlike growth factorI) Body mass index (BMI) 18.027.0 kg/m^2 (both inclusive) Considered generally healthy upon completion of medical history, physical examination, vital signs, screening laboratory results, and electrocardiogram (ECG), as judged by the Investigator The receipt of any investigational medicinal product within 1 month prior to this trial Current or previous treatment with recombinant human growth hormone or IGFI Female of childbearing potential who is pregnant, breastfeeding or intends to become pregnant or is not using adequate contraceptive methods (adequate contraceptive measures as required by local law) for the duration of the trial Known presence or history of malignancy Diabetes mellitus Use of pharmacologic doses of glucocorticoids Use of anabolic steroids History of drug or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>